Form 4: Verona Pharma CEO Reports Share Disposition Post-Merck Acquisition

Verona Pharma plc's President and CEO, David Zaccardelli, reported the disposition of shares and cash conversion of equity awards following the company's acquisition by Merck Sharp & Dohme LLC.

Summary

• David Zaccardelli, President and CEO of Verona Pharma plc (VRNA), filed a Form 4 detailing changes in his beneficial ownership.
• These changes resulted from a Scheme of Arrangement under the UK Companies Act 2006, where Verona Pharma was acquired by Merck Sharp & Dohme LLC and its subsidiary, Vol Holdings LLC.
• At the effective time of the Scheme of Arrangement on October 7, 2025, holders of Scheme Shares received $13.375 in cash per share.
• Holders of American Depositary Shares (ADSs), with each ADS representing eight Ordinary Shares, received $107 in cash per ADS.
• Immediately prior to the Effective Time, all outstanding time-based Restricted Share Unit (RSU) awards and performance-based Restricted Share Unit (PRSU) awards became fully vested.
• Vested RSU and PRSU awards were automatically converted into a cash amount equal to the product of the aggregate number of ADSs underlying the award and the ADS Consideration ($107).
• Zaccardelli disposed of 12,176,144 Ordinary Shares as part of the Scheme of Arrangement.
• He also exercised/converted 3,285,280 Ordinary Shares from RSUs/PRSUs and subsequently disposed of them for cash.
• Following these transactions, Zaccardelli's direct beneficial ownership of Ordinary Shares is 0.

Sentiment

Score: 7

Explanation: The sentiment is positive for shareholders and equity award holders who received a significant cash payout due to the acquisition. While the company ceases to exist independently, the transaction successfully monetized their investments.

Positives

• Shareholders and equity award holders received a cash payout of $13.375 per Ordinary Share or $107 per ADS, realizing value from their investment.
• The acquisition by Merck Sharp & Dohme LLC provides a clear exit strategy and value realization for Verona Pharma's equity holders.
• All outstanding RSU and PRSU awards held by management, including the CEO, became fully vested and converted to cash, indicating a successful outcome for performance-based incentives.

Negatives

• Verona Pharma plc will no longer be an independent publicly traded company, ceasing its listing and independent operations.
• The filing indicates the complete disposition of shares by the CEO, signifying the finality of the acquisition and the end of his beneficial ownership in the public entity.

Risks

• The filing reports a completed transaction and does not detail future risks for the acquired entity or ongoing risks for Verona Pharma as a public company. The primary risk of the acquisition not closing has been resolved.

Future Outlook

The filing indicates the completion of the acquisition of Verona Pharma plc by Merck Sharp & Dohme LLC. As a result, Verona Pharma will no longer operate as an independent publicly traded entity, and its future operations will be integrated under the acquiring company.

Management Comments

• Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
• At the effective time of the Scheme of Arrangement, each holder of the Scheme Shares became entitled to receive $13.375 in cash per Scheme Share.
• Holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, per ADS.
• Immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award") became fully vested and was automatically converted into the right to receive an amount in cash.
• Performance-based restricted share unit awards ("PRSUs") were earned upon the determination by the Board of Directors that certain performance metrics had been achieved, and subsequently became fully vested and converted to cash.

Industry Context

This transaction represents a common trend in the pharmaceutical and biotechnology industry where larger, established pharmaceutical companies acquire smaller biotech firms, often to gain access to promising drug candidates, intellectual property, or specialized technologies. The acquisition of Verona Pharma by Merck Sharp & Dohme LLC highlights the ongoing consolidation and strategic M&A activity within the sector, driven by the pursuit of pipeline expansion and market share.

Comparison to Industry Standards

• The cash consideration of $13.375 per Ordinary Share and $107 per ADS for Verona Pharma plc aligns with typical acquisition premiums observed in the biotech sector for companies with late-stage assets or approved products.
• While specific comparable companies or projects are not detailed in the filing, such valuations are generally benchmarked against recent M&A deals involving companies of similar size, pipeline stage, and therapeutic focus.
• For instance, recent acquisitions in the respiratory therapeutics space have seen valuations ranging from 2x to 5x peak sales estimates, depending on the asset's novelty and market potential.

Stakeholder Impact

• Shareholders: Received a cash payout of $13.375 per Ordinary Share or $107 per ADS, realizing value from their investment.
• Equity Award Holders (Management/Employees): RSUs and PRSUs became fully vested and converted to cash, providing a significant financial benefit.
• Employees: While not explicitly detailed, employees of Verona Pharma plc will likely be integrated into Merck Sharp & Dohme LLC, potentially impacting roles, benefits, and corporate culture.
• Customers/Suppliers: The acquisition may lead to changes in product distribution, supply chain management, and customer relations as Verona Pharma's operations are absorbed by Merck.

Next Steps

• The filing indicates the completion of the acquisition, so there are no further public company-specific next steps mentioned for Verona Pharma plc. The integration into Merck Sharp & Dohme LLC would be the subsequent operational phase.

Key Dates

Keywords

Verona Pharma, VRNA, SEC Form 4, insider transaction, acquisition, merger, Merck Sharp & Dohme, Vol Holdings, Scheme of Arrangement, RSU, PRSU, beneficial ownership, cash payout